Navigation Links
Gene therapy advance treats hemophilia in mouse models

tively small amount of the normal protein level is needed to make the problem milder and, thus, less life threatening.

"Hemophilia is considered an ideal candidate for correction with gene therapy because if you could just raise the factor VIII activity from less than 1 percent of normal to within 5 to 10 percent of normal, the tendency for spontaneous bleeding and need for hospitalization would diminish dramatically," McCray said.

"In the mouse model in our study, we were able to achieve levels of gene expression that converted the hemophilia A in the mouse from a severe to a mild form. The correction lasted 30 weeks -- the duration of the study," he added.

One of the current treatments for hemophilia involves intravenously delivering recombinant (genetically engineered) human factor VIII protein to prevent bleeding episodes. However, the weekly to bi-weekly preventive treatments are extremely expensive, costing up to $500,000 per year. In addition, over time some patients may develop antibodies to the protein, making the treatments less effective.

In earlier studies, McCray's team, which includes Yubin Kang, M.D., at the time a UI assistant research scientist in pediatrics (now a UI resident in internal medicine), targeted the liver because its main functional cells, called hepatocytes, can make the factor VIII protein and secrete it into the bloodstream. However, the investigators recognized the need to target the liver more effectively.

"It has been difficult to conclusively identify the cells that normally make factor VIII," McCray said. "Hepatocytes may not be the main source of this protein, but they are relatively easy to target. So we aimed to find a way to get these cells to make more of it. In effect, we're using the hepatocytes as a factory to make this protein and secrete it into the bloodstream."

To better target the hepatocytes in the mice, the team took the disabled protein coat from the baculovirus A
'"/>

Source:University of Iowa


Page: 1 2 3

Related biology news :

1. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
2. Columbia research lifts major hurdle to gene therapy for cancer
3. Combination therapy boosts effectiveness of telomere-directed cancer cell death
4. Gene therapy converts dead bone graft to new, living tissue
5. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
8. New therapy for HIV/AIDS eliminates needles and excessive toxicity
9. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
10. Gene therapy for Parkinsons disease moves forward in animals
11. Pulsating ultrasound enhances gene therapy for tumors
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene therapy advance treats hemophilia mouse models

(Date:5/27/2015)... 27, 2015   Codonics (codonics.com), ... and image documentation solutions and Omnicell ... automation solutions, is pleased to announce their ... Safe Label System® (SLS), an award-winning FDA ... the Omnicell Anesthesia Workstation, helps prevent medication ...
(Date:5/22/2015)... -- According to a new market research ... Emotion, Forensic), by Software (Middleware, Databases), by Hardware (Cameras, Integrated ... Home) - Global Forecast to 2020", published by MarketsandMarkets, ... 2015 to $6.19 Billion by 2020, at a CAGR ... Tables and   43 Figures spread through 140 Pages ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. ... that its wholly owned subsidiary, 3D-ID LLC, a company ... Team Battelle for the biometrics technology portion of the ... Contract from the Department of the Army. ... products developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... 2009 - Collaboration in prostate cancer translational research in ... achieved in recent years but also to streamline current ... overlaps. This was amongst the goals of the two-day ... opened today in Amsterdam, The Netherlands. "It ...
... Outstanding International Horticulturist Award from the American Society for ... recognition of her longstanding and valuable contribution to international ... award on 25 July 2009 at the annual ASHS ... co-editor of the books Genetics and Genomics of Rosaceae ...
... -- Predation is one of the most fundamental and fascinating ... predators on Earth. However, their hunting pattern is difficult to ... a result, shark predatory behavior has remained much of a ... using geographic profiling -- a criminal investigation tool used to ...
Cached Biology News:Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues 2Prostate Cancer Translational Research in Europe meeting: Search for biomarkers continues 3Geographic profiling applied to track hunting patterns of white sharks in South Africa 2
(Date:6/2/2015)... , June 02, 2015 Research ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad definition ... be objectively measured and evaluated as an indicator ... as pharmacological responses to a therapeutic intervention. Tests ...
(Date:6/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/l5jcdk/genotyping_market ) has announced ... Application & by Products - Global Forecast to 2020" ... genotyping market is expected to reach $17.0 Billion in ... of 22.3% during the forecast period of 2015 to ... the availability of a range of products for wide ...
(Date:6/2/2015)... --  Hospira, Inc. (NYSE: HSP ), a ... – a global biopharmaceutical company – has received approval ... Brazil – for Remsima (infliximab), ... Brazil . The medication will be ... infliximab in 26 European countries and in ...
(Date:6/2/2015)... “Stem Cell Therapy to help dogs suffering from ... used often as an adjunct to surgery in large specialty ... aware or comfortable enough with the techniques to offer it ... for the last resort cases - when nothing else works ... paw to get around. It is an easy procedure, and ...
Breaking Biology Technology:Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3Genotyping Market Report 2015 by Technology, Application & by Products - Global Forecast to 2020 for the $17 Billion Market 2ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3
... ChemoCentryx, Inc. today announced positive preclinical results for its ... the American Society of Nephrology. CCR2 inhibition in diabetic ... serum markers of renal function, and hyperglycemia.  These data ... Inhibition in Diabetic Mice Results in a Rapid and ...
... Nov. 10, 2011 Sequenom, Inc. (NASDAQ: SQNM ... today announced the Company,s participation at the Lazard Capital Markets ... York City November 15-16, 2011. Harry F. Hixson, ... Director and EVP of Research and Development, will present on ...
... The report " Lung Cancer Drugs ... http://www.marketsandmarkets.com/Market-Reports/lung-cancer-drugs-market-508.html ] " analyzes and studies the major ... Browse in-depth TOC on   ... 2020). Get Free 10% ...
Cached Biology Technology:ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 2ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 3Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 2MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 3MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020 4
Mouse monoclonal antibody to ST8SIA2 - ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
...
Biology Products: